Literature DB >> 12792542

Vertical (two-layer) skin grafting: new reserves for autologic skin.

Leonid Kogan1, Jacky Govrin-Yehudain.   

Abstract

The main, permanent source of burn coverage continues to be autologic skin. In patients with major burns, the amount of available autologic skin may be insufficient. Consequently, severe wounds are covered after debridement with other biological or synthetic skin substitutes. Another source of skin reserves for wound coverage is the use of cultured keratinocyte sheet graft alone or with any dermal substitute. Some of these materials provide only temporal coverage and are often costly and time-consuming in preparation. These factors can be critical in burned patients. To expand the effective means of wound coverage, the authors sought a new source of autologic skin. The dermal grafts that were the marginal product of skin harvesting were meshed and grafted on the debrided third-degree burn, granulated wound, or muscle. The authors observed good dermal grafts "take" with rapid or slow epithelialization. They saw no the delay in donor site healing where the skin grafts overlapped. The histological difference in usual skin grafts and dermal grafts was studied after their harvesting and "taking."

Entities:  

Mesh:

Year:  2003        PMID: 12792542     DOI: 10.1097/01.SAP.0000044150.03940.4E

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  2 in total

1.  Intensive insulin treatment increases donor site wound protein synthesis in burn patients.

Authors:  Demidmaa Tuvdendorj; Xiao-Jun Zhang; David L Chinkes; Asle Aarsland; Gabriela A Kulp; Marc G Jeschke; David N Herndon
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

2.  Donor site wound protein synthesis correlates with length of acute hospitalization in severely burned children.

Authors:  Demidmaa Tuvdendorj; David L Chinkes; Xiao-Jun Zhang; Asle Aarsland; David N Herndon
Journal:  Wound Repair Regen       Date:  2010-04-14       Impact factor: 3.617

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.